-
Goldman's 7 Favorite Biotech Ideas For 2016
Wednesday, September 7, 2016 - 4:13pm | 410Read More...Goldman Sachs highlighted seven favorite stocks in the biotech sector for the second half of the current year. These stocks offer upside potential between 13 percent and 175 percent. Bluebird bio Inc (NASDAQ: BLUE) provides the biggest upside potential, with 175 percent, whereas Agilent...
-
AbbVie Shares Trading At A Discount To Other Pharmaceuticals; Argus Reaffirms With A Buy Rating
Monday, August 8, 2016 - 1:23pm | 314Read More...David Toung and Casey Meyers, analysts at Argus Research, reaffirmed a Buy rating on AbbVie Inc (NYSE: ABBV) on Monday with an $85 price target following the company's "strong" second quarter earnings print. The analysts noted that not only were AbbVie's results driven by sales of Humira and...
-
In Barclays' View, 2016's Second Half Looks 'Noisy' For AbbVie
Monday, August 1, 2016 - 11:30am | 389Read More...AbbVie Inc (NYSE: ABBV) reported another beat and raise quarter, with the 2Q revenue and EPS beating the consensus expectations. Barclays’ Geoff Meacham maintains an Equal-Weight rating on the company, with a price target of $68. Meacham mentioned that while execution remains consistent, 2H16...
-
Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform
Wednesday, June 29, 2016 - 1:56pm | 242Read More...Biogen Inc (NASDAQ: BIIB) has an aging MS franchise, but a solid biosimilar pipeline is sure to offset the loss of Tecfidera, Avonex and Tysabri. Bernstein's Aaron Gal initiated Biogen at outperform and set a price target of $282. The multiple sclerosis franchise has a five-year runway as...
-
The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers
Monday, April 25, 2016 - 1:57pm | 335Read More...The meat of large-cap pharmaceutical earnings season starts this week. Johnson & Johnson (NYSE: JNJ)’s strong Q1 report last week has Credit Suisse analyst Vamil Divan hopeful that AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and Eli Lilly and Co (NYSE: LLY) will be able...
-
AbbVie Falling After Q4 Report, 2016 Guidance Affirmation
Friday, January 29, 2016 - 9:14am | 240Read More...Shares of AbbVie Inc (NYSE: ABBV) were trading lower by more than 4 percent early Friday morning after the company reported its fourth quarter results. AbbVie earned $1.13 per share in the fourth quarter on revenue of $6.36 billion. Wall Street analysts were expecting the company to earn $1.12...
-
Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent
Monday, June 29, 2015 - 2:44pm | 375Read More...Last Friday, Amgen, Inc. (NASDAQ: AMGN) filed an intellectual property rights (IPR) suit against AbbVie Inc (NYSE: ABBV)’s 8,916,157 patent, which claims an innovative formulation for Humira. According to IPR timelines, AbbVie should file a response to Amgen’s petition in three...
-
Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices
Friday, February 20, 2015 - 2:10pm | 329Read More...In a report published Friday, Jefferies analyst Jeffrey Holford named AbbVie Inc (NASDAQ: ABBV) as a "Top Global Pick" in the Pharmaceutical space, replacing Pfizer Inc. (NYSE: PFE). Holford added that shares have seen significant pressure since mid-December as the initial...
-
What Are The Best-Selling Drugs Of 2014?
Friday, October 3, 2014 - 11:34am | 759Read More...What are the top-selling pharmaceutical drugs of the year? While 2014 is not yet over, it's possible to explore to answer to this question after making a few educated assumptions. According to research from IMS Health, a healthcare services, information and technology provider, the top...
